AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
The Pharma Letter4 天
Enhertu added to China's health insurance plan
AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
Daily4 天
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
pharmaphorum4 天
NICE blames companies for breakdown in Enhertu talks
Dr Sam Roberts, NICE chief executive, said AstraZeneca and Daiichi Sankyo had not offered a fair price for the drug Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available ...
pharmaphorum4 天
Surprise Enhertu rejection follows NICE process change
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.